Scott Pomeroy

Publications

1. An Approach to Successful Development of Clinician-Scientists in Neurology: The NINDS R25 Experience. Ann Neurol. 2024 Oct; 96(4):625-632. View Abstract
2. WNT signalling control by KDM5C during development affects cognition. Nature. 2024 Mar; 627(8004):594-603. View Abstract
3. Developmental basis of SHH medulloblastoma heterogeneity. Nat Commun. 2024 Jan 08; 15(1):270. View Abstract
4. Clinical variants paired with phenotype: A rich resource for brain gene curation. Genet Med. 2024 03; 26(3):101035. View Abstract
5. Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma. Nat Genet. 2023 Dec; 55(12):2189-2199. View Abstract
6. Recognizing and Responding to the Needs of Future Child and Adult Neurology Care Through the Evolution of Residency Training. Ann Neurol. 2023 12; 94(6):1005-1007. View Abstract
7. Global neurology: It's time to take notice. Ann Clin Transl Neurol. 2023 05; 10(5):842-845. View Abstract
8. Validation of a computational phenotype for finding patients eligible for genetic testing for pathogenic PTEN variants across three centers. J Neurodev Disord. 2022 03 23; 14(1):24. View Abstract
9. SEQing to find hidden medulloblastoma cells. Cancer Cell. 2021 11 08; 39(11):1452-1454. View Abstract
10. Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. J Clin Oncol. 2021 08 20; 39(24):2685-2697. View Abstract
11. TORC1/2 kinase inhibition depletes glutathione and synergizes with carboplatin to suppress the growth of MYC-driven medulloblastoma. Cancer Lett. 2021 04 28; 504:137-145. View Abstract
12. Loss of Consciousness in the Young Child. Pediatr Cardiol. 2021 Feb; 42(2):234-254. View Abstract
13. Crisis Standard of Care: Management of Infantile Spasms during COVID-19. Ann Neurol. 2020 08; 88(2):215-217. View Abstract
14. Epigenetics and survivorship in pediatric brain tumor patients. J Neurooncol. 2020 Oct; 150(1):77-83. View Abstract
15. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2020 02; 139(2):223-241. View Abstract
16. Single-Cell Transcriptomics in Medulloblastoma Reveals Tumor-Initiating Progenitors and Oncogenic Cascades during Tumorigenesis and Relapse. Cancer Cell. 2019 09 16; 36(3):302-318.e7. View Abstract
17. Intellectual and developmental disabilities research centers: Fifty years of scientific accomplishments. Ann Neurol. 2019 09; 86(3):332-343. View Abstract
18. Resolving medulloblastoma cellular architecture by single-cell genomics. Nature. 2019 08; 572(7767):74-79. View Abstract
19. Medulloblastoma. Nat Rev Dis Primers. 2019 02 14; 5(1):11. View Abstract
20. Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell. 2018 09 10; 34(3):396-410.e8. View Abstract
21. Rapid discrimination of pediatric brain tumors by mass spectrometry imaging. J Neurooncol. 2018 Nov; 140(2):269-279. View Abstract
22. Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncol. 2018 06; 19(6):785-798. View Abstract
23. Brain cancer genomics and epigenomics. Handb Clin Neurol. 2018; 148:785-797. View Abstract
24. The whole-genome landscape of medulloblastoma subtypes. Nature. 2017 07 19; 547(7663):311-317. View Abstract
25. MicroRNA-1301 suppresses tumor cell migration and invasion by targeting the p53/UBE4B pathway in multiple human cancer cells. Cancer Lett. 2017 08 10; 401:20-32. View Abstract
26. The evolution of medulloblastoma therapy to personalized medicine. F1000Res. 2017; 6:490. View Abstract
27. Medulloblastoma: Molecular Classification-Based Personal Therapeutics. Neurotherapeutics. 2017 04; 14(2):265-273. View Abstract
28. OTX2 Activity at Distal Regulatory Elements Shapes the Chromatin Landscape of Group 3 Medulloblastoma. Cancer Discov. 2017 03; 7(3):288-301. View Abstract
29. Tracking the Fate of Cells in Health and Disease. N Engl J Med. 2016 Dec 22; 375(25):2494-2496. View Abstract
30. SMARCB1-mediated SWI/SNF complex function is essential for enhancer regulation. Nat Genet. 2017 Feb; 49(2):289-295. View Abstract
31. The Evolution of Child Neurology Training. Pediatr Neurol. 2017 01; 66:3-4. View Abstract
32. First In Vivo Testing of Compounds Targeting Group 3 Medulloblastomas Using an Implantable Microdevice as a New Paradigm for Drug Development. J Biomed Nanotechnol. 2016 Jun; 12(6):1297-302. View Abstract
33. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016 06; 131(6):821-31. View Abstract
34. DiSCoVERing Innovative Therapies for Rare Tumors: Combining Genetically Accurate Disease Models with In Silico Analysis to Identify Novel Therapeutic Targets. Clin Cancer Res. 2016 08 01; 22(15):3903-14. View Abstract
35. A clinic devoted to peer victimization in special needs children. Ann Neurol. 2016 Feb; 79(2):167-8. View Abstract
36. Incidence, risk factors, and longitudinal outcome of seizures in long-term survivors of pediatric brain tumors. Epilepsia. 2015 Oct; 56(10):1599-604. View Abstract
37. Defining the molecular landscape of ependymomas. Cancer Cell. 2015 May 11; 27(5):613-5. View Abstract
38. WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathol Commun. 2014 Dec 24; 2:174. View Abstract
39. The G protein a subunit Gas is a tumor suppressor in Sonic hedgehog-driven medulloblastoma. Nat Med. 2014 Sep; 20(9):1035-42. View Abstract
40. Could a5-GABA-A receptor activation be used as a target for managing medulloblastomas? CNS Oncol. 2014 Jul; 3(4):245-7. View Abstract
41. Modelling high myc medulloblastoma and other brain tumors using human neural stem cells. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii4. View Abstract
42. CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathol. 2014 Aug; 128(2):291-303. View Abstract
43. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014 Mar 17; 25(3):393-405. View Abstract
44. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature. 2014 Feb 27; 506(7489):445-50. View Abstract
45. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014 Mar 20; 32(9):886-96. View Abstract
46. A developmental program drives aggressive embryonal brain tumors. Nat Genet. 2014 Jan; 46(1):2-3. View Abstract
47. Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. Acta Neuropathol. 2014 Feb; 127(2):189-201. View Abstract
48. a5-GABAA receptors negatively regulate MYC-amplified medulloblastoma growth. Acta Neuropathol. 2014 Apr; 127(4):593-603. View Abstract
49. Inactivation of the tumor suppressor WTX in a subset of pediatric tumors. Genes Chromosomes Cancer. 2014 Jan; 53(1):67-77. View Abstract
50. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013 Dec; 126(6):917-29. View Abstract
51. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013 Nov; 14(12):1200-7. View Abstract
52. Message from the incoming editor. Ann Neurol. 2013 Sep; 74(3):A9-A10. View Abstract
53. Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. J Clin Oncol. 2013 Aug 10; 31(23):2927-35. View Abstract
54. Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nat Genet. 2013 Aug; 45(8):927-32. View Abstract
55. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc Natl Acad Sci U S A. 2013 May 14; 110(20):8188-93. View Abstract
56. Clinical practice guidelines and practice parameters for the child neurologist. J Child Neurol. 2013 Jul; 28(7):917-25. View Abstract
57. Activation of ß-catenin/TCF targets following loss of the tumor suppressor SNF5. Oncogene. 2014 Feb 13; 33(7):933-8. View Abstract
58. A novel syndrome caused by the E410K amino acid substitution in the neuronal ß-tubulin isotype 3. Brain. 2013 Feb; 136(Pt 2):522-35. View Abstract
59. Sport-related concussion: time to take notice. Curr Opin Pediatr. 2012 Dec; 24(6):687-8. View Abstract
60. Medulloblastomics: the end of the beginning. Nat Rev Cancer. 2012 Dec; 12(12):818-34. View Abstract
61. Medulloblastoma biology in the post-genomic era. Future Oncol. 2012 Dec; 8(12):1597-604. View Abstract
62. Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 2012 Aug 02; 488(7409):106-10. View Abstract
63. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature. 2012 Aug 02; 488(7409):49-56. View Abstract
64. Dissecting the genomic complexity underlying medulloblastoma. Nature. 2012 Aug 02; 488(7409):100-5. View Abstract
65. Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncol. 2012 Aug; 13(8):838-48. View Abstract
66. Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors. Cell Cycle. 2012 May 15; 11(10):1956-65. View Abstract
67. Sleep dysfunction in long term survivors of craniopharyngioma. J Neurooncol. 2012 Jul; 108(3):543-9. View Abstract
68. Hedgehog-GLI pathway in medulloblastoma. J Clin Oncol. 2012 Jun 10; 30(17):2154-6. View Abstract
69. Pleiotropic effects of miR-183~96~182 converge to regulate cell survival, proliferation and migration in medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):539-52. View Abstract
70. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012 Apr; 123(4):473-84. View Abstract
71. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012 Apr; 123(4):465-72. View Abstract
72. MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathol. 2012 Apr; 123(4):529-38. View Abstract
73. Recent advances in autism spectrum disorders. Curr Opin Pediatr. 2011 Dec; 23(6):607-8. View Abstract
74. Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol. 2012 Apr; 123(4):615-26. View Abstract
75. Posterior fossa ependymomas: a tale of two subtypes. Cancer Cell. 2011 Aug 16; 20(2):133-4. View Abstract
76. Neuro-oncology training for the child neurology resident. Semin Pediatr Neurol. 2011 Jun; 18(2):120-2. View Abstract
77. Training the next generation of child neurologists - a neuroscience based approach. Ann Neurol. 2011 Jun; 69(6):A9-A10. View Abstract
78. Molecular fingerprints of medulloblastoma and their application to clinical practice. Future Oncol. 2011 Mar; 7(3):327-9. View Abstract
79. Predicting relapse in patients with medulloblastoma by integrating evidence from clinical and genomic features. J Clin Oncol. 2011 Apr 10; 29(11):1415-23. View Abstract
80. UBE4B promotes Hdm2-mediated degradation of the tumor suppressor p53. Nat Med. 2011 Mar; 17(3):347-55. View Abstract
81. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun. 2011 Feb 01; 2:180. View Abstract
82. miR-34a confers chemosensitivity through modulation of MAGE-A and p53 in medulloblastoma. Neuro Oncol. 2011 Feb; 13(2):165-75. View Abstract
83. Long-term clinical outcomes following treatment of childhood craniopharyngioma. Pediatr Blood Cancer. 2011 Jul 01; 56(7):1120-6. View Abstract
84. Growing spectrum and relevance of pediatric neuro-immunology. Curr Opin Pediatr. 2010 Dec; 22(6):717. View Abstract
85. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10; 29(11):1424-30. View Abstract
86. Loss of the tumor suppressor Snf5 leads to aberrant activation of the Hedgehog-Gli pathway. Nat Med. 2010 Dec; 16(12):1429-33. View Abstract
87. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell. 2010 Oct 19; 18(4):316-28. View Abstract
88. Neuralized1 causes apoptosis and downregulates Notch target genes in medulloblastoma. Neuro Oncol. 2010 Dec; 12(12):1244-56. View Abstract
89. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18; 463(7283):899-905. View Abstract
90. Human TUBB3 mutations perturb microtubule dynamics, kinesin interactions, and axon guidance. Cell. 2010 Jan 08; 140(1):74-87. View Abstract
91. Frequent amplification of a chr19q13.41 microRNA polycistron in aggressive primitive neuroectodermal brain tumors. Cancer Cell. 2009 Dec 08; 16(6):533-46. View Abstract
92. Pathologic intracellular signaling in childhood pilocytic astrocytomas. Neurology. 2009 Nov 10; 73(19):1522-3. View Abstract
93. Melatonin deficiency and disrupted circadian rhythms in pediatric survivors of craniopharyngioma. Neurology. 2009 Jul 28; 73(4):323-5. View Abstract
94. Pediatric sleep medicine in 2008: state-of-the-art. Curr Opin Pediatr. 2008 Dec; 20(6):639-40. View Abstract
95. Loss of the epigenetic tumor suppressor SNF5 leads to cancer without genomic instability. Mol Cell Biol. 2008 Oct; 28(20):6223-33. View Abstract
96. Cardiac risk after craniopharyngioma therapy. Pediatr Neurol. 2008 Apr; 38(4):256-60. View Abstract
97. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008 Apr 01; 22(7):884-93. View Abstract
98. Schwann cell proliferation during Wallerian degeneration is not necessary for regeneration and remyelination of the peripheral nerves: axon-dependent removal of newly generated Schwann cells by apoptosis. Mol Cell Neurosci. 2008 May; 38(1):80-8. View Abstract
99. Introduction: survivors of childhood cancer: the new face of developmental disabilities. Dev Disabil Res Rev. 2008; 14(3):183-4. View Abstract
100. Gain of 1q is a potential univariate negative prognostic marker for survival in medulloblastoma. Clin Cancer Res. 2007 Dec 01; 13(23):7022-8. View Abstract
101. Moyamoya following cranial irradiation for primary brain tumors in children. Neurology. 2007 Mar 20; 68(12):932-8. View Abstract
102. Overlay analysis of the oligonucleotide array gene expression profiles and copy number abnormalities as determined by array comparative genomic hybridization in medulloblastomas. Genes Chromosomes Cancer. 2007 Jan; 46(1):53-66. View Abstract
103. Molecular genetics of pediatric central nervous system tumors. Curr Oncol Rep. 2006 Nov; 8(6):423-9. View Abstract
104. Medulloblastoma outcome is adversely associated with overexpression of EEF1D, RPL30, and RPS20 on the long arm of chromosome 8. BMC Cancer. 2006 Sep 12; 6:223. View Abstract
105. Transverse myelitis after therapy for primitive neuroectodermal tumors. Pediatr Neurol. 2006 Aug; 35(2):122-5. View Abstract
106. Medulloblastoma Subtypes Defined by Gene Expression Analysis 864. Neurosurgery. 2006 Aug 01; 59(2):475. View Abstract
107. Everyday cognitive function after craniopharyngioma in childhood. Pediatr Neurol. 2006 Jan; 34(1):13-9. View Abstract
108. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci U S A. 2005 Dec 06; 102(49):17745-50. View Abstract
109. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005 Oct 25; 102(43):15545-50. View Abstract
110. Ataxia and shaking in a 2-year-old girl: acute marijuana intoxication presenting as seizure. Pediatr Emerg Care. 2005 Aug; 21(8):527-8. View Abstract
111. A novel role for extracellular signal-regulated kinase 5 and myocyte enhancer factor 2 in medulloblastoma cell death. Cancer Res. 2005 Jul 01; 65(13):5683-9. View Abstract
112. Diencephalic syndrome: a cause of failure to thrive and a model of partial growth hormone resistance. Pediatrics. 2005 Jun; 115(6):e742-8. View Abstract
113. INI1 protein expression distinguishes atypical teratoid/rhabdoid tumor from choroid plexus carcinoma. J Neuropathol Exp Neurol. 2005 May; 64(5):391-7. View Abstract
114. Continuous remission of newly diagnosed and relapsed central nervous system atypical teratoid/rhabdoid tumor. J Neurooncol. 2005 Mar; 72(1):77-84. View Abstract
115. Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial. Int J Radiat Oncol Biol Phys. 2005 Feb 01; 61(2):374-9. View Abstract
116. Craniopharyngioma therapy: long-term effects on hypothalamic function. Neurologist. 2005 Jan; 11(1):55-60. View Abstract
117. Intracerebral abscess in children: historical trends at Children's Hospital Boston. Pediatrics. 2004 Jun; 113(6):1765-70. View Abstract
118. Neural development and the ontogeny of central nervous system tumors. Neuron Glia Biol. 2004 May; 1(2):127-33. View Abstract
119. Conserved mechanisms across development and tumorigenesis revealed by a mouse development perspective of human cancers. Genes Dev. 2004 Mar 15; 18(6):629-40. View Abstract
120. Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol. 2004 Mar 15; 22(6):994-8. View Abstract
121. Molecular biology of medulloblastoma therapy. Pediatr Neurosurg. 2003 Dec; 39(6):299-304. View Abstract
122. Pediatric brain tumors. Neurol Clin. 2003 Nov; 21(4):897-913. View Abstract
123. Medulloblastoma tumorigenesis diverges from cerebellar granule cell differentiation in patched heterozygous mice. Dev Biol. 2003 Nov 01; 263(1):50-66. View Abstract
124. Progressive myoclonus in a child with a deep cerebellar mass. Neurology. 2003 Sep 23; 61(6):829-31. View Abstract
125. Marked regression of metastatic pilocytic astrocytoma during treatment with imatinib mesylate (STI-571, Gleevec): a case report and laboratory investigation. J Pediatr Hematol Oncol. 2003 Aug; 25(8):644-8. View Abstract
126. Neuropsychological functioning after surgery in children treated for brain tumor. Neurosurgery. 2003 Jun; 52(6):1348-56; discussion 1356-7. View Abstract
127. Magnetic resonance imaging of patched heterozygous and xenografted mouse brain tumors. J Neurooncol. 2003 May; 62(3):259-67. View Abstract
128. Application of microarrays to neurological disease. Arch Neurol. 2003 May; 60(5):676-82. View Abstract
129. A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma. Int J Radiat Oncol Biol Phys. 2003 Apr 01; 55(5):1182-5. View Abstract
130. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003 Apr 01; 63(7):1602-7. View Abstract
131. Medulloblastomas and primitive neuroectodermal tumors rarely contain polyomavirus DNA sequences. Neuro Oncol. 2002 07; 4(3):165-70. View Abstract
132. High-resolution imaging demonstrates dynein-based vesicular transport of activated Trk receptors. J Neurobiol. 2002 Jun 15; 51(4):302-12. View Abstract
133. Focus on central nervous system neoplasia. Cancer Cell. 2002 Mar; 1(2):125-8. View Abstract
134. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 2002 Jan 24; 415(6870):436-42. View Abstract
135. Memory deficits among children with craniopharyngiomas. Neurosurgery. 2001 Nov; 49(5):1053-7; discussion 1057-8. View Abstract
136. Psychometric testing in bacterial meningitis: results of a long-term prospective study of infants and children treated between 1973 and 1977. J Child Neurol. 2001 Nov; 16(11):854-7. View Abstract
137. Children with headache suspected of having a brain tumor: a cost-effectiveness analysis of diagnostic strategies. Pediatrics. 2001 Aug; 108(2):255-63. View Abstract
138. Analysis of the SDHD gene, the susceptibility gene for familial paraganglioma syndrome (PGL1), in pheochromocytomas. J Clin Endocrinol Metab. 2001 Jun; 86(6):2890-4. View Abstract
139. Circulating serpin tumor markers SCCA1 and SCCA2 are not actively secreted but reside in the cytosol of squamous carcinoma cells. Int J Cancer. 2000 Jul 20; 89(4):368-77. View Abstract
140. Identification of PATCHED mutations in medulloblastomas by direct sequencing. Hum Mutat. 2000 Jul; 16(1):89-90. View Abstract
141. Neurological dysfunction associated with postoperative cerebellar mutism. J Neurooncol. 2000 May; 48(1):75-81. View Abstract
142. A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron. 2000 May; 26(2):405-16. View Abstract
143. Biology and pathobiology of neuronal development. Ment Retard Dev Disabil Res Rev. 2000; 6(1):41-6. View Abstract
144. Rapid nuclear responses to target-derived neurotrophins require retrograde transport of ligand-receptor complex. J Neurosci. 1999 Sep 15; 19(18):7889-900. View Abstract
145. Basal ganglia germinoma with progressive cerebral hemiatrophy. Pediatr Neurol. 1999 Apr; 20(4):312-4. View Abstract
146. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab. 1999 Mar; 84(3):895-8. View Abstract
147. Activation of neurotrophin-3 receptor TrkC induces apoptosis in medulloblastomas. Cancer Res. 1999 Feb 01; 59(3):711-9. View Abstract
148. Human immunodeficiency virus type 1 long terminal repeat quasispecies differ in basal transcription and nuclear factor recruitment in human glial cells and lymphocytes. J Biomed Sci. 1998; 5(1):31-44. View Abstract
149. Neurotrophins in cerebellar granule cell development and medulloblastoma. J Neurooncol. 1997 Dec; 35(3):347-52. View Abstract
150. Activation of ErbB2 during wallerian degeneration of sciatic nerve. J Neurosci. 1997 Nov 01; 17(21):8293-9. View Abstract
151. Trk receptors function as rapid retrograde signal carriers in the adult nervous system. J Neurosci. 1997 Sep 15; 17(18):7007-16. View Abstract
152. Abnormal cerebellar development and foliation in BDNF-/- mice reveals a role for neurotrophins in CNS patterning. Neuron. 1997 Aug; 19(2):269-81. View Abstract
153. Postnatal addition of satellite cells to parasympathetic neurons. J Comp Neurol. 1996 Nov 18; 375(3):518-25. View Abstract
154. Magnetic resonance imaging changes after stereotactic radiation therapy for childhood low grade astrocytoma. Cancer. 1996 Aug 15; 78(4):864-73. View Abstract
155. Axonal growth and fasciculation linked to differential expression of BDNF and NT3 receptors in developing cerebellar granule cells. J Neurosci. 1995 Jul; 15(7 Pt 1):4970-81. View Abstract
156. Neurobehavioral and neurologic outcome in long-term survivors of posterior fossa brain tumors: role of age and perioperative factors. J Child Neurol. 1995 May; 10(3):209-12. View Abstract
157. Hemorrhagic vasculopathy after treatment of central nervous system neoplasia in childhood: diagnosis and follow-up. AJNR Am J Neuroradiol. 1995 Apr; 16(4):693-9. View Abstract
158. Expression of the neurotrophin receptor TrkC is linked to a favorable outcome in medulloblastoma. Proc Natl Acad Sci U S A. 1994 Dec 20; 91(26):12867-71. View Abstract
159. The p53 tumor suppressor gene and pediatric brain tumors. Curr Opin Pediatr. 1994 Dec; 6(6):632-5. View Abstract
160. Stereotactic radiotherapy for pediatric and adult brain tumors: preliminary report. Int J Radiat Oncol Biol Phys. 1994 Oct 15; 30(3):531-9. View Abstract
161. Advances in radiation therapy for craniopharyngiomas. Pediatr Neurosurg. 1994; 21 Suppl 1:101-7. View Abstract
162. Vital imaging of glomeruli in the mouse olfactory bulb. J Neurosci. 1992 Mar; 12(3):976-88. View Abstract
163. Seizures and other neurologic sequelae of bacterial meningitis in children. N Engl J Med. 1990 Dec 13; 323(24):1651-7. View Abstract
164. Postnatal construction of neural circuitry in the mouse olfactory bulb. J Neurosci. 1990 Jun; 10(6):1952-66. View Abstract
165. Neuron/glia relationships observed over intervals of several months in living mice. J Cell Biol. 1988 Sep; 107(3):1167-75. View Abstract
166. Effect of morphine injectedin periadueductal gray on the activity of single units in nucleus raphe magnus of the rat. Brain Res. 1978 Jun 23; 149(1):266-9. View Abstract
Show All Publications Show Fewer Publications